The number of projects in drug development that fail in late phases because of cardiac side effects such as QT prolongation can impede drug discovery and development of projects. The molecular target responsible for QT prolongation by a wide range of pharmaceutical agents is the myocardial hERG potassium channel. It is therefore desirable to screen for compound interactions with the hERG channel at an early stage of drug development. Here, the authors report a cell-based fluorescence assay using membrane potential-sensitive fluorescent dyes and stably transfected hERG channels from CHO cells. The assay allows semiautomated screening of compounds for hERG activity on 384-well plates and is sufficiently rapid for testing a large number of compounds. The assay is robust as indicated by a Z′ factor larger than 0.6. The throughput is in the range of 10,000 data points per day, which is significantly higher than any other method presently available for hERG. The data obtained with the fluorescence assay were in qualitative agreement with those from patch-clamp electrophysiological analysis. There were no false-positive hits, and the rate of false-negative compounds is currently 12% but might be further reduced by testing compounds at higher concentration. Quantitative differences between fluorescence and electrophysiological methods may be due to the use-or voltage-dependent activity of the antagonists. (Journal of Biomolecular Screening 2005:339-347) 
h ERG OR KCNH2 BELONGS TO THE FAMILY of ether-a-gogo-like genes originally discovered in Drosophila and encodes a potassium channel whose activity is critical for the repolarization at the end of a cardiac action potential. Loss-of-function mutations in this channel are associated with a potentially lethal inherited long QT syndrome (LQT), a disorder that predisposes one to torsades de pointes and ventricular fibrillation. [1] [2] [3] However, the QT interval is more frequently prolonged by medications that block cardiac K + channels. [4] [5] [6] Many commonly used therapeutic agents have been shown to elicit a prolongation of the QT interval and an increased risk of torsade de pointes, [7] [8] [9] [10] [11] [12] which are found among distinct classes of compounds used in various therapeutic areas including antiarrhythmics, antibiotics, antihistamines, antipsychotics, and gastrointestinal prokinetic agents. For example, torsade de pointes has been reported to occur in 1% to 3% of patients treated with the antimalarial quinidine, 1% to 5% of those treated with sotalol and dofetilide, and up to 12.5% of patients treated with the antiarrhythmic agent ibutilide. [13] [14] [15] The results of the Cardiac Arrhythmia Suppression Trial exemplify the problem of druginduced arrhythmias. 16 Regulatory authorities now regard the ability of a compound to inhibit the hERG channel as an important indication of its possible LQT liability. 17 Thus, the sensitivity of hERG K + channels to drugs has become a major issue in drug development as it is seen as allowing a good prediction of potentially dangerous cardiac side effects.
The number of methods available for functional hERG channel measurement is, however, limited. At present, screening for long QT liability in the pharmaceutical industry is performed by patch clamp on hERG transfected cells or isolated cardiac myocytes, Rb + efflux measurements, microelectrode recording from cardiac tissues (e.g., Purkinje fibers), or in vivo electrocardiogram recording ( Table 1 ). The widely accepted standard method for monitoring the potassium channel function is patch-clamp electrophysiology. However, this method is labor intensive, has a low throughput, and thus does not meet today's need for quickly profiling hits from high-throughput screening (HTS).
Assays based on membrane potential-sensitive fluorescent dyes have been pursued as a potential alternative in the search for a high-throughput readout from potassium channel targets.
These assays exploit the properties of dyes that, upon alteration of the cell membrane potential, either
• relocate from the outside to the inside of the cells (or vice versa), which causes an alteration in fluorescence intensity, 18 or • flip between the inner and the outer sides of the membrane bilayer, thereby enabling the dyes to perform fluorescence resonance energy transfer with another dye at the outer side of the membrane. 19 One of the most widely used membrane potential dyes is the bis-oxonol DiBAC 4 (3) whose distribution across biological membranes depends on the membrane potential. Depolarized cells accumulate the negatively charged oxonol dye and increase its fluorescence. Conversely, hyperpolarization is indicated by a decrease in fluorescence. Good agreement was found between absolute membrane potential data from human peripheral blood lymphocytes, estimated by flow cytometry using DiBAC 4 (3), and results of parallel patch-clamp measurements. 20 Thus, if the membrane potential depends on potassium conductance, the fluorescence signal change can be used as a surrogate marker of potassium channel function and should indicate an inhibition of the channels by any test compound. Automated pipetting and the short readout time of fluorescent assays (384 wells in~30 s) are sufficiently rapid for HTS of compounds.
Although these techniques cannot match the accuracy of the gold standard in ion channel research, the patch-clamp technique, the lower cost and the higher throughput render them an alternative to electrophysiological tests for screening large numbers of compounds (Table 1) . 21 Below, we describe the evaluation of a fluorescence assay for detecting the effect of drug-like compounds on the hERG potas-sium channel. The assay is based on the assumption that the hERG potassium channel activity contributes to the resting membrane potential in permanently transfected cells, and thus a block of hERG channels should result in a depolarization of the cell membrane. Although the assay does not provide the sensitivity of patchclamp electrophysiology, it can be used to eliminate potent hERG active compounds from consideration for further development.
MATERIALS AND METHODS

Chemicals
Chemicals were purchased from Sigma (Buchs, Switzerland), Merck (Dietikon, Switzerland), and Calbiochem (Darmstadt, Germany). DiBAC 4 (3) was from Molecular Probes (Lucerne, Switzerland). Fluorometric imaging plate reader (FLIPR) Membrane Potential Assay Kit (FMP) was from Molecular Devices (Epalinges, Switzerland).
] carbonyl]methanesulfonanilide, 2HCl}} and haloperidol, potent inhibitors of the hERG potassium channel, were used as reference compounds. E4031 was purchased from Calbiochem (Darmstadt, Germany); haloperidol was obtained in house. E4031 was used as a positive control at the following concentrations: 2.5 µM, 0.5 µM, 0.1 µM, and 0.01 µM.
Cell culture
CHO cell lines (wild type and stably transfected with hERG) were provided by Evotec OAI AG (Hamburg, Germany). Cells 32, 33 Human channels in cultured mammalian cells
Amount of rubidium lost from cells
Low cost, high throughput (≥100 IC 50 /d) functional assay
Long loading procedure of the cells followed by a thorough wash; limited correlation with patch clamp HTS using cell-based assays 23, 29 Human channels in cultured mammalian cells
Membrane potential
Low cost, high throughput (≥100 IC 50 /d) functional assay Nonspecific interactions, limited correlation with patch clamp ECG = electrocardiogram; APD 50/90 = action potential duration; APA = action potential amplitude; V max = depolarization rate; HTS = high-throughput screening.
were grown in 175 cm 2 flasks (Falcon, Milian SA, Genève, Switzerland) in 40 ml MEM ALPHA medium (Gibco Invitrogen AG, Basel, Switzerland) supplemented with 5% (v/v) fetal calf serum, 1% (v/v) L-glutamine solution (Gibco Invitrogen AG, Basel, Switzerland), and G-418 (geneticine; 800 µg/ml) at 37°C and 5% CO 2 . Effective G418 concentration may vary from batch to batch. It is advisable to adjust the G418 concentration for every batch individually in control cells. CHO wild-type cells were grown without G418, but 1% (v/v) of a penicillin/streptomycin/L-glutamine solution was added.
Cells were split in a Monday-Wednesday-Friday-Monday routine at about 70% to 80% confluence.
First, the old medium was removed and the cells were washed with an EDTA solution containing 136.9 mM NaCl, 5.37 mM KCl, 11.06 mM Na 2 HPO 4 • H 2 O, 5 mM NaH 2 PO 4 • H 2 O, 10.09 mM glucose, 0.94 mM Na 2 EDTA, and 0.028 µM phenol red (pH 7.4). Then, 3 to 4 ml trypsin-EDTA solution was added (1/10 dilution with EDTA, which corresponds to~0.025% trypsin; Sigma, Buchs, Switzerland, 0.25% Trypsin-EDTA). When more than 95% of the cells are in suspension (usually after 2 min), the trypsin activity was stopped by addition of 10 ml medium and gentle trituration (3-4 times). The cells were washed once with medium, counted, and adjusted to 2 × 10 5 /ml by using a Cedex Counter (Innovatis, Ismatec SA, Glattbrugg-Zürich, Switzerland). Finally, the cells were seeded (50 µl/well) into 384-well microplates (Falcon ® Microtest™ Assay Plate, black clear flat-bottom TC surface, sterile, Becton Dickinson, Heidelberg, Germany). The cells were incubated for about 15 to 20 h at 37°C and 5% CO 2 .
Membrane potential assay
This fluorescence-based assay uses the potentiometric fluorescent dyes (e.g., bis-[1,3-dibutylbarbituric acid]trimethine oxonol, or DiBAC 4 (3) and FMP dye) that partition across the membrane in a voltage-dependent manner ( Fig. 1 ). 22 The cells (CHO-hERG and CHO wild type) were grown adherent on 384-well microplates for about 15 to 20 h at 37°C and 5% CO 2 . The culture medium was removed from the cells, which were immediately covered with 10 µl HEPES buffer using a Multidrop 384 pipettor (Catalys AG, Wallisellen, Switzerland). HEPES (N-[2-Hydroxyethyl]piperazine-N′-[2-ethanesulfonic acid]) buffer contains 10 mM HEPES, pH 7.2, physiological salt concentrations and the dye DiBAC 4 (3) and FMP. The composition of the buffer is proprietary to Evotec OAI. DiBAC 4 (3) was used at a final concentration of 4 µM. The FMP dye was dissolved according to the supplier's protocol in 10 ml buffer, but in contrast to the FMP protocol, it could be used in the hERG fluorescence assay in a 50-fold higher dilution.
Compounds to be tested in the assay were dissolved in DMSO to yield a stock solution of 10 mM. A total of 200 µl of a 150 µM compound dilution was pipetted manually into a GREINER 96well plate (GREINER Bio-One VACUETTE Schweiz GmbH, St. Gallen, Switzerland). Compound dilutions and transfer (15 µl) to 384-well plates were performed using the TECAN Genesis Robotic Sample Processor 150 workstation (TECAN Schweiz AG Männedorf, Switzerland). A total of 60 µl buffer A (1% DMSO in HEPES buffer including the dye) was added to the separate sample plate containing the diluted test compounds using the Multidrop 384, and then 50 µl of this compound solution was transferred to the cells by a TECAN GenMate 96-multichannel pipettor.
Compounds were tested in triplicate at 25 µM, 5 µM, 1 µM, and 0.1 µM against CHO-hERG and CHO wild-type cells. The test compounds were applied to both cell types on the same microplate to avoid plate-to-plate differences.
End points, observable by no further increase of fluorescence despite increased concentration of compounds, were determined after 3 and 5 h. DiBAC 4 (3) fluorescence signals were measured after 3-and 5-h incubation using a BMG POLARstar fluorescence reader (BMG Labtechnologies, Offenburg, Germany): excitation wavelength 485 nM (12 nM bandwidth), emission wavelength 520 nM (35 nM bandwidth). The fluorescence of the FMP dye was measured after 3 and 5 h with a TECAN Safire monochromator reader (TECAN Schweiz AG, Männedorf, Switzerland): excitation wavelength 540 nM, emission wavelength 555 nM (bandwidth 2.5 nM). The readout time for a 384-well plate was ≤30 s for both readers. The assay was performed in black Falcon 384-well clear-bottom plates, and fluorescence was measured from below.
Data analysis
The digital data generated by the fluorescence reader were analyzed with Microsoft Excel and the Microsoft Excel add-in XLfit3 The resulting changes in fluorescence intensity in control cells (CHO wt) were subtracted from changes in CHO-hERG cells to correct for nonspecific compound effects (e.g., quenching).
Normalized relative fluorescence was calculated as follows:
where y = normalized relative fluorescence increase ∆F c = relative fluorescence increase in CHO-hERG cells in the presence of compound corrected for fluorescence changes seen in control cells (CHO wt) ∆F comp, max = maximal fluorescence increase (∆F c ) in the presence of a high concentration of the test compound or of 1 µM E4031 (whichever was larger)
For E4031 (1 µM), the average value of ∆F E4031, max was 77% after 3 h and 86% after 5 h using the fluorescent dye DiBAC 4 (3). All results from a given plate were discarded if ∆F E4031, max was less than 50%. By using FMP dye, the average value of ∆F E4031, max was determined as >300% after 3 h and 5 h, and no plates had to be discarded because of insufficient increase of fluorescence. The time course of fluorescence, measured every 30 min for 5 h, showed a continuous increase of fluorescence until reaching a plateau after 230 to 300 min. However, the time until reaching this plateau is also dependent-to some extent-on the type of substance added to the hERG cells. E4031 was always present in some wells as a positive control.
For calculating IC 50 values, the relative fluorescence increase must be normalized between the maximum and minimum signals, which correspond to a maximal or zero blockage of the hERG potassium channel. If the compound-induced increase of fluorescence did not reach an end point (saturation) within the tested concentration range, this was most likely due to an incomplete blockage of hERG potassium channels. End points, observed as no further increase of fluorescence of the voltage-sensitive dye despite increased concentration of compounds, were clearly obtained with, for example, the methanesulfonanilide compounds E4031 and dofetilide ( Fig. 2A) . Therefore, the normalization was performed using the fluorescence increase caused by a saturating concentration (1 µM) of E4031.
Patch-clamp electrophysiology
During the whole-cell patch-clamp experiments, the cells were continuously superfused by a saline solution containing 150 mM NaCl, 10 mM KCl, 1mM MgCl 2 , 3 mM CaCl 2 , and 10 mM HEPES, pH 7.4. Compounds for testing were dissolved in DMSO at a concentration of 10 mM and diluted with the saline solution to the desired concentrations. The glass micropipettes for whole-cell patch-clamp recording were filled with another saline solution mimicking the composition of the cytoplasm, that is, containing 110 mM KCl mV, and the hERG K + channels were activated once every 10 s by a voltage pulse pattern consisting of a 1-s depolarization to 20 mV followed by a 20-ms hyperpolarization to -120 mV. The amplitude of the transient inward current at -120 mV was used for the analysis. After recording 18 control responses, the test compound was applied to the cell under investigation from a nearby capillary, usually for 3 min per concentration. Current amplitude values were plotted versus time to visualize the effect of the compound and calculate the percentage of hERG channel inhibition (y). The data were then fitted by the equation (4) to obtain the IC 50 value (x, concentration, and H, Hill coefficient).
RESULTS AND DISCUSSION
Reproducibility of the hERG fluorescence assay
The assay we evaluated is based on the use of fluorescent dyes (e.g., bis-[1,3-dibutylbarbituric acid]trimethine oxonol or DiBAC 4 (3) and FMP dye), which accumulate inside cells upon depolarization of the membrane potential, leading to elevated fluorescence ( Fig. 1 ). 22 Initial experiments were focused on optimizing the dye concentration, loading time, use of suspended cells versus adherently grown cells, cell density, and the DMSO tolerance of the cells (1% DMSO is tolerated, data not shown). In cell-based assays, factors such as cell viability and seeding density can influence the signal and in consequence the screening results. For this reason, we first investigated the reproducibility of the hERG fluorescence assay (HT-hERG assay) using the 2 different membrane potential-sensitive fluorescent dyes DiBAC 4 (3) and the FMP dye. Reproducibility was shown in 2 different ways. First, the IC 50 values for E4031 were compared in different assays on different days. The results are shown in Figure 2B . With both dyes similar, IC 50 values were measured. Over a number of experiments, we derived an average IC 50 value for E4031 of 0.04 ± 0.02 µM (n = 37) by the use of DiBAC 4 (3) and of 0.03 ± 0.016 µM (n = 94) for the FMP dye. The IC 50 value was within the preset quality limit of 3-fold variation in about 86% of the experiments (32 of 37 DiBAC 4 (3) experiments and 80 of 94 FMP dye assays) underlining the high quality of this assay.
Because the change of fluorescence occurs minutes after the change of membrane potential, such dyes are best suited to detecting steady-state changes in membrane potential. DiBAC 4 (3), which was originally used by Evotec OAI (Hamburg, Germany), belongs to a class of membrane potential-sensitive dyes that have a slow response time caused by the relatively slow migration of the oxonol across the lipid bilayer.
The FMP dye, on the other hand, was shown to be up to 14-fold faster than DiBAC 4 (3) in response to polarization 23 and was in our hands superior to DiBAC 4 (3) with respect to the E4031-induced increase of fluorescence as mentioned above (Materials and Meth-ods, assay description). After introduction of an hERG antagonist, fluorescence signals increase by >300% equivalent to an increase of about 10,000 relative fluorescence units (rfu) to about 30,000 to 40,000 rfu (data not shown). These values are dependent on the adjusted gain of the instrument; thus, the relative increase of fluorescence was used for the calculations. A comparison of the 2 dyes is shown on the Web page of Molecular Devices (www. moleculardevices.com) describing FLIPR ® Membrane Potential Assay Kit and in the publication of Baxter et al. 23 We observed maximal increase of fluorescence after about 3 h using DiBAC 4 (3) and after about 30 to 60 min with FMP. However, the IC 50 value still decreases continuously with increasing incubation time until no further change is observed. This final value (saturation) is reached with FMP and DiBAC 4 (3) after 2 to 3 h and 3 to 4 h, respectively. Because this kinetic is dependent on the kind of hERG antagonist, we measured the fluorescence after 3 and 5 h. As FMP was superior to DiBAC 4 (3), we decided to perform further evaluation of the assay using the FMP dye.
In a 2nd series of experiments, we compared the IC 50 values of different compounds tested at least twice on different dates (Fig.  3) . The values rarely differ by more than 2-fold (dotted lines) from one experiment to the other. Data points on the diagonal line correspond to identical values in both experiments. In addition, the R 2 value of 0.75 indicates that the HT-hERG assay had a sufficiently good reproducibility to be qualified for HTS.
The robustness of the HT-hERG assay could also have been demonstrated by the calculation of the Z′ factor, 24 which is a characteristic parameter of the quality of the assay. A Z′ factor of >0.6 was calculated for different experiments using CHO cells stably expressing the hERG potassium channel in the presence of 0.5 µM E4031 (data not shown). A Z′ factor of >0.5 is regarded as suitable for HTS.
Comparison of HT-hERG assay and patch-clamp analysis
Patch clamping is the gold standard for determining ion channel function. In the patch-clamp whole-cell configuration, the electrical potential difference across the cell membrane is fixed to directly assess the current carried by ions crossing the membrane. This technology provides a high selectivity and resolution for any changes in the electrical membrane conductance.
For a pharmacological characterization of the fluorescence assay, compounds interacting with the hERG potassium channel were tested and the data compared with known results from patchclamp experiments. Figure 4 shows a plot of the log(IC 50 ) values obtained in both types of assay. As part of the patch clamp, IC 50 values were taken from the literature, and they may include some dependence on experimental conditions such as saline composition or voltage pulse duration. Nevertheless, the 2 IC 50 values of the 2 methods correlate reasonably with an R 2 value of 0.6. The fluorescence assay was clearly able to identify hERG channel inhibitors but could not reliably rank compounds of similar potency.
We then tested compounds from several lead optimization programs at Hoffmann-La Roche and compared the IC 50 values determined by the HT-hERG assay with IC 50 values from patch clamping by calculating the quotient of the values.
A quotient smaller than 1 is observed if the IC 50 values measured in the HT-hERG assay are lower than those determined in patch clamp. For most compounds, however, the IC 50 obtained in the HT-hERG assay was higher than that in patch clamp, resulting in quotients larger than 1 (median = 5.2, 95% confidence range = 0.7-77). Experiments to partially depolarize the cells by increasing KCl concentration did not result in a better correlation with the patch-clamp data. In contrast, the increase of KCl concentration resulted in a reduced fluorescence signal. One should keep in mind that in patch clamp experiments, the membrane potential is switched between rather negative and positive values (-120 to + 20 mV) whereas addition of KCl results in a moderate steady-state depolarization (to approximately -20 mV, data not shown).
The log(IC 50 ) values of the compounds taken from our lead optimization programs are shown in Figure 5 . Again, it is obvious that most IC 50 values from the HT-hERG assay are higher than the values from electrophysiology. In addition, the correlation is relatively weak (R 2 = 0.37). Thus, the HT fluorescence method should be used only for a qualitative identification of hERG channel blockers. Any ranking of the IC 50 values from the HT assay is questionable when screening diverse compounds unless the values are very different (>100-fold). As discussed above, this may be due to the fact that compounds may interfere with the hERG channel in a use-dependent manner. Generally, the IC 50 values obtained in the fluorescence assay were equal or higher than the values measured in patch-clamp electrophysiology; thus, the true potency of the compounds was rarely overestimated. For explaining the observation that the IC 50 values measured by fluorescence are higher than those for patch clamp, it should be remembered that the fluorescent dye is an indication of membrane potential rather than the potassium membrane conductance. It has been suggested that a large fraction of potassium channels must be blocked before the membrane potential starts to change ("spare channel hypothesis"). 25 In addition, it is known that many compounds may block the hERG potassium channel in a voltage-and use-dependent manner (e.g., cisapride, 26 verapamil, 27 astemizol 28 ). This means that in patch-clamp analysis, the compound more efficiently blocks the hERG channel if the membrane potential is set to more positive values. Because the membrane potential cannot be controlled in the fluorescence assay, the effect of use-dependent blockers may be underestimated.
Limitations of identifying potential hERG activity by the HT-hERG assay
At an early stage of drug development, the percentage of falsepositive results in any counter screen should be low to avoid a premature exclusion of otherwise promising compounds. At a later stage, safety concerns become more important, and false-negative results are less acceptable.
We therefore compared the results (IC 50 data) of the HT-hERG assay with those obtained from patch-clamp analysis in regard to the detection of hERG activity (Fig. 6 ).
In about 88% of the cases, there was at least qualitative agreement between the 2 assay systems. For 73% of the tested compounds, an IC 50 value below 25 µM was obtained in HT-hERG and patch clamp ("active" compounds). About 15% of the compounds were inactive (IC 50 > 25 µM) in both test systems. There were no false-positive compounds, that is, if hERG activity was identified in the HT-fluorescence assay, the compound also blocked the potassium current in patch-clamp experiments. The fraction of compounds that had an IC 50 value >25 µM in the HT-hERG assay but were active in patch-clamp experiments (false negatives) was 12%. To know what proportion of the 12% of false negatives showed activity in the membrane potential, we tested these compounds at the highest concentration of 100 µM. The IC 50 values for 20% of these compounds were in the range between 25 and 50 µM; for 24%, between 50 and 100 µM; and for 56%, the IC 50 values were >100 µM (data not shown).
The IC 50 values obtained in the HT-hERG assay are, on average, 5 times higher than patch-clamp IC 50 s, so some of the false negatives might not be within the limit of detection. In view of the median ratio of 5.2 between the IC 50 values determined by fluorescence and patch clamp, 25 µM was probably not high enough for detecting the effect of all hERG inhibitors in the fluorescence assay. In addition, intrinsic fluorescence of the test compounds, a problem in all fluorescence assays, may have prevented the correct identification of some hERG inhibitors.
All assays based on the use of membrane potential-sensitive dyes rely on an indirect readout, that is, the membrane potential, and do not reflect the behavior of the ion channels under investigation. They are prone to fluorescence or quenching artifacts, and in the case of FLIPR 22, 23 and Voltage/Ion Probe Reader, 29 an additional constraint may arise from the costs of purchasing these measuring devices. Although binding assays are nonfunctional assays, their IC 50 values correlate well for some hERG blockers with values determined by other methods. 30 However, other examinations performed with [ 3 H]dofetilide yielded larger discrepancies (e.g., for E4031, haloperidol and terfenadine) compared with patchclamp data. 31 As compounds interact with different binding sites on the hERG channel, further investigations might be necessary to investigate the concentration-response relationships of compounds with hERG. Unlike binding assays, functional interactions of compounds with the hERG channel can be studied by flux assays. Although good correlations of rubidium flux assays with electrophysiological investigations has been shown for some hERG blockers (e.g., dofetilide), 32, 33 other research groups have reported larger discrepancies when voltage-sensitive or state-dependent compounds were tested. 32 The patch-clamp method has been regarded as the gold standard to study pharmacological effects of drugs on ion channels, but the manual handling of this method is the limiting factor for the throughput. During the past few years, the 1st generation of automated patch-clamp systems was developed by different companies. Different automated high-throughput patch-clamp machines were discussed in a review by Wood et al. 34 In all types of patchclamp systems, including the automated techniques, the conditions of stimulation and the selected solutions may influence the results and should be considered in the experiments. Nevertheless, in the next few years, this new technology can probably address hERG Potassium Channel Inhibition Journal of Biomolecular Screening 10(4); 2005 www.sbsonline.org 345 FIG. 6. Detection limit of hERG activity by HT-hERG assay using the FMP dye and patch clamp (PC). Seventy-three percent of the compounds were identified as hERG active in both assays (correlation of IC 50 values shown in Fig. 4 ). Fifteen percent were inactive in both assays, and 12% were found active in patch clamp only (false negative in the HT-hERG assay). Compounds inactive in the patch-clamp experiments were never active in the HT-hERG assay, that is, there are no false-positive results. The total number of tested compounds was 263.
bottlenecks in secondary and safety assays. However, the costs and the still moderate throughput may restrict the application of automated patch-clamp to HTS. Thus, the lack of better assay systems and the low cost and high throughput of the fluorescence assay in comparison with any electrophysiological system make the HT-hERG useful for screening a large number of compounds that otherwise cannot be evaluated.
To summarize, the fluorescence assay can be used for the identification of potential hERG channel blockers during early drug development. However, during later steps in the development process, when the aim is a fine-tuned optimization of a given lead structure by chemical modification, the assay may not be sufficiently accurate.
From an HTS perspective, slow redistribution dyes limit throughput. But under the current assay conditions, which allowed an end point determination and a readout time of just 30 s for a 384well plate, the throughput was increased to 10,000 data points per day (≥400 IC 50 values/d), which is superior to other systems.
CONCLUSIONS
We have evaluated a fluorescence assay for detecting hERG potassium channel inhibitors. The assay was robust, as indicated by a Z′ factor larger than 0.6, which was calculated for repeated tests of 0.5 µM E4031. This value and the throughput achieved are suitable for profiling corporate compound collections. The HT-hERG assay did not produce any false-positive hits so far, suggesting that this assay reduces the risk of eliminating potentially promising compounds in the early stages of development. The rate of falsenegative compounds is currently 12% but might be further reduced by testing compounds at higher concentration. The assay was optimized for use with 384-well plates but can be performed in 1536well plates as well. The current throughput is in the range of 10,000 data points on a full automation system, which is significantly higher than any other presently available methods for hERG ( Table 1) .
